Guide

How GLP-1 Drugs Interact With Common Prescriptions: A Clinical Guide (2026)

Last updated: April 18, 2026 · 18 min read · Reviewed by Grey Peptides Editorial Board

TL;DR

Millions of Americans are now on semaglutide, tirzepatide, or a compounded GLP-1 analog, and most of them are also on at least one other prescription medication. The drug-interaction picture is better-characterized than peptide medicine generally — because GLP-1 agonists have completed FDA approval, their prescribing information explicitly documents interactions with commonly co-prescribed drugs. The most clinically important interactions fall into four groups: (1) other glucose-lowering drugs (insulin, sulfonylureas, DPP-4 inhibitors) — additive hypoglycemia or redundant pathway activation; (2) oral medications with narrow absorption windows (oral contraceptives, levothyroxine, warfarin) — delayed gastric emptying alters absorption and timing; (3) drugs whose dose requirements change with weight loss (warfarin, levothyroxine, antihypertensives, antiseizure medications) — substantial weight reduction often requires dose adjustment of medications the patient was stable on for years; and (4) combinations with specific contraindications or warnings (pancreatitis history, thyroid C-cell considerations). This article walks through each group, the specific FDA-labeled warnings, the clinical monitoring that pharmacists and prescribers actually follow, and how to have the right conversation with your prescribing physician. Every section is sourced to FDA prescribing information, peer-reviewed pharmacology literature, or established clinical references. It is not a substitute for a pharmacist consultation.

Table of Contents

  1. Why this article exists
  2. How GLP-1 agonists work (and why that matters for interactions)
  3. The delayed gastric emptying problem
  4. Interactions with other glucose-lowering drugs
  5. Oral contraceptives and the absorption question
  6. Levothyroxine and the weight-loss double effect
  7. Warfarin, DOACs, and bleeding risk
  8. Antihypertensives and dose adjustments after weight loss
  9. Antidepressants and mood stabilizers
  10. Statins, cardiovascular drugs, and CYP metabolism
  11. NSAIDs, opioids, and pain medication timing
  12. Contraindications and boxed warnings
  13. How to have the conversation with your physician
  14. A note about compounded GLP-1s
  15. Sources

Why this article exists

A pharmacist friend once described GLP-1 agonists as "the most interaction-rich weight-loss drugs we've ever had in community pharmacy." That framing is correct. Other weight-loss pharmacotherapy — orlistat, phentermine, naltrexone/bupropion — has far fewer and less clinically significant interactions than semaglutide or tirzepatide do. The GLP-1 class is rich in interactions not because it is dangerous, but because it does three things at once that each independently interact with other medications:

  1. It slows gastric emptying, which changes how every oral medication is absorbed.
  2. It substantially reduces body weight over months of use, which changes the pharmacokinetics of many drugs dosed on a weight-sensitive basis.
  3. It alters glucose handling, which interacts directly with any other glucose-lowering therapy and indirectly with medications that are affected by blood sugar.

Most patients who start on a GLP-1 already have a list of other medications. The statistical profile of people who get prescribed semaglutide for type 2 diabetes includes high rates of hypertension, hyperlipidemia, antidepressant use, thyroid disease, and cardiovascular medication use. Among people starting semaglutide or tirzepatide for weight management, the most common concurrent medications are oral contraceptives, SSRIs, statins, and antihypertensives.

This article is the companion piece to the Peptide-Drug Interaction Database. The database lets you search a specific drug and see documented peptide interactions. This article is the narrative version for the single peptide class that most patients care most about — GLP-1 agonists — because that is where the interaction questions are real, specific, and have concrete answers in the FDA-approved labeling.

How GLP-1 agonists work (and why that matters for interactions)

GLP-1 (glucagon-like peptide-1) is an incretin hormone released from intestinal L-cells after a meal. Its native half-life in the body is about two minutes — it is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). The medications in this class (semaglutide, liraglutide, dulaglutide, exenatide, and the dual agonist tirzepatide, plus the investigational triple agonist retatrutide) are modified versions of GLP-1 that resist DPP-4 degradation, giving them half-lives measured in days rather than minutes.

Their actions include:

  • Enhanced glucose-dependent insulin secretion. Pancreatic β-cells release more insulin in response to rising blood glucose, but not in response to normal glucose — which is why the hypoglycemia risk is relatively low on GLP-1 monotherapy.
  • Suppressed glucagon secretion. Reduces hepatic glucose output.
  • Delayed gastric emptying. Food stays in the stomach longer, which reduces post-meal glucose spikes and is a major driver of satiety.
  • Central nervous system effects on satiety. GLP-1 receptors in the hypothalamus and brainstem reduce appetite.
  • Weight loss. Over 12–18 months of sustained use, weight reduction of 12–25% of baseline is typical.

Four of these five actions have direct implications for drug interactions. Only the glucagon suppression is relatively self-contained. The rest — glucose-dependent insulin, delayed gastric emptying, CNS satiety effects, and weight loss — each change the drug-handling profile of the person taking the medication.

The delayed gastric emptying problem

The single most broadly important interaction mechanism across the GLP-1 class is delayed gastric emptying. It is not a side effect to be feared; it is part of how the drug works. But it means that every oral medication taken by a patient on semaglutide or tirzepatide is absorbed on a different timeline than it was before the GLP-1 was started.

The magnitude is not trivial. Semaglutide delays gastric emptying modestly at first dose and the effect diminishes over time as the body adapts. Tirzepatide produces a more pronounced and persistent delay — one reason it has more aggressive labeled warnings about oral contraceptives than semaglutide does.

What this means in practice:

  • Oral medications with narrow therapeutic windows (warfarin, digoxin, levothyroxine, lithium, some antiseizure drugs) become harder to dose consistently. The drug still gets absorbed, but the absorption curve is flattened and shifted. Steady-state exposure is usually preserved, but peak concentrations may drop.
  • Medications where a rapid peak matters (short-acting benzodiazepines for procedural anxiety, opioids for acute pain, oral contraceptives taken at a consistent daily time) may have meaningfully altered timing.
  • Medications bundled with meals (enzyme replacement, iron supplements) interact with delayed emptying in ways that depend on specific formulation.

The FDA's approach across the approved GLP-1 labels has been consistent: acknowledge the theoretical risk, note which specific drugs have been studied, and make specific recommendations only where the data supports them. The labels for Ozempic and Wegovy (semaglutide) are less aggressive than the labels for Mounjaro and Zepbound (tirzepatide) on this point, which is itself a signal that the tirzepatide effect is larger.

Interactions with other glucose-lowering drugs

This is the most clinically obvious interaction category — and the one where real patient harm has occurred when it was not managed carefully.

Insulin (any formulation). Adding a GLP-1 agonist to ongoing insulin therapy produces additive glucose-lowering. Hypoglycemia risk rises substantially, especially during titration. The FDA labels for every GLP-1 agonist recommend reducing insulin dose before or at initiation, with further adjustment during titration. In practice, endocrinologists typically reduce basal insulin by 15–30% at semaglutide start and 20–40% at tirzepatide start, then adjust from blood glucose monitoring. Patients not on insulin who are nonetheless taking intensive glycemic monitoring should be aware that blood sugar will run lower than they expect for the first month.

Sulfonylureas (glipizide, glimepiride, glyburide). Same mechanism-level concern as insulin, different absolute risk. Sulfonylureas cause insulin release regardless of glucose levels, so the additive hypoglycemia risk is real. Most endocrinologists will halve the sulfonylurea dose at GLP-1 initiation and then taper off the sulfonylurea entirely over a few months if glucose control allows. Long-term combination therapy with a sulfonylurea plus a GLP-1 is not preferred; the sulfonylurea is usually the one to discontinue.

DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin). This is the "don't combine" case. DPP-4 inhibitors work by raising endogenous GLP-1 levels. Adding exogenous GLP-1 to a DPP-4 inhibitor produces redundant pathway activation without additive A1c reduction — you get GI side effects without clinical benefit. The American Diabetes Association's Standards of Care explicitly discourages routine co-prescription. If a patient is on a DPP-4 inhibitor and is starting a GLP-1, the DPP-4 inhibitor is discontinued.

Metformin. No interaction. Metformin works through a completely different mechanism (reduced hepatic glucose output, possible gut microbiome effects). Metformin plus a GLP-1 agonist is one of the most common combinations in modern type 2 diabetes care. Both cause GI side effects, and the combination can be additive in the first weeks — but once tolerance develops, the combination is well-tolerated and pharmacologically independent.

SGLT2 inhibitors (empagliflozin, dapagliflozin). No interaction. Different mechanisms (renal glucose excretion vs incretin). The combination is increasingly common in type 2 diabetes and heart failure management. Monitor for additive volume depletion in elderly patients.

Oral contraceptives and the absorption question

This is the most specific and most labeled interaction in the entire GLP-1 class, and the rule is different between semaglutide and tirzepatide.

Tirzepatide (Mounjaro, Zepbound). The FDA label is explicit and unusual in its specificity. It recommends that patients on oral contraceptives switch to a non-oral method, or add a barrier method, for four weeks after tirzepatide initiation and for four weeks after each dose escalation. This warning is based on pharmacokinetic studies showing that tirzepatide reduces oral contraceptive exposure enough to matter. The labeling is unusual because most drug labels say "may reduce efficacy" without the specific four-week window — the specificity here reflects actual study data.

Semaglutide (Ozempic, Wegovy). The FDA label does not carry the same specific warning. Semaglutide produces less pronounced gastric emptying delay than tirzepatide, and the labeled language is closer to "no clinically significant interaction demonstrated." In practice, some prescribers still recommend a backup method during titration out of mechanism-based caution, but this is not FDA labeling.

Retatrutide. Investigational. Not yet FDA-approved. Based on the mechanism (larger gastric emptying effect than even tirzepatide), it is reasonable to assume the tirzepatide-style warning will apply if retatrutide gains approval.

The practical takeaway for patients: if you are starting tirzepatide and rely on oral contraception, read the label warning and discuss non-oral alternatives with your physician. This is not theoretical — the labeling change that introduced this warning was based on specific PK data showing meaningful reduction in contraceptive exposure. If you are starting semaglutide, the concern is lower but not zero; the conservative approach is to use backup methods during the first dose escalation.

Levothyroxine and the weight-loss double effect

Levothyroxine (Synthroid and generics) is the most commonly prescribed thyroid hormone replacement, and it is a classic case of two GLP-1 effects compounding: delayed gastric emptying plus weight loss.

The gastric emptying effect. Levothyroxine absorption is notoriously sensitive to gastric conditions. It requires morning fasting administration and is routinely disrupted by calcium, iron, coffee, and food. Delayed gastric emptying from a GLP-1 slows levothyroxine absorption and can shift peak plasma levels. The effect is modest in most patients but can be clinically detectable in those on tight TSH control.

The weight-loss effect. Levothyroxine is dosed by body weight. Patients who lose 15–25% of their body weight on tirzepatide or semaglutide typically need a levothyroxine dose reduction — not because the drug interacts with the peptide, but because the optimal dose for a 220-pound patient is different than for a 170-pound patient. The TSH will rise (indicating relative overmedication) as weight drops if the dose is not adjusted.

Clinical monitoring approach. Endocrinology practice is to recheck TSH 6–12 weeks after GLP-1 initiation, and again after any significant weight change. Dose reductions in the 12–25% range are typical. A patient who was stable on 100 mcg levothyroxine for years may need 75 mcg or 88 mcg after six months of tirzepatide. This is a common adjustment, not an unusual one.

The timing principle: take levothyroxine in the morning on an empty stomach, and keep that timing consistent. Do not take it at the same time as the GLP-1 injection. (The GLP-1 is weekly; levothyroxine is daily — they do not overlap anyway.)

Warfarin, DOACs, and bleeding risk

Warfarin is the anticoagulant most affected by starting a GLP-1. Two compounding effects:

Absorption timing. Delayed gastric emptying changes warfarin absorption. The half-life is long enough that total exposure is usually preserved, but INR variability may increase.

Weight loss and metabolic changes. Warfarin metabolism is affected by albumin levels, which shift with weight change, and by body composition. Patients who were stable on a particular INR range for years often need warfarin dose adjustment during weight loss.

The practical approach is simple but often skipped: increase INR monitoring frequency during the first three months of GLP-1 therapy, and after any significant weight change. Weekly or biweekly INRs for the first month are reasonable. Dose adjustments of 10–20% in either direction are common.

DOACs (apixaban/Eliquis, rivaroxaban/Xarelto, dabigatran/Pradaxa). The situation is meaningfully different. DOACs do not require INR monitoring and are less sensitive to absorption variability because they are dosed to produce consistent anticoagulation rather than titrated to a lab value. The interaction concern is lower. Some DOACs (dabigatran) have pronounced pH sensitivity and may be more affected by gastric emptying changes; apixaban and rivaroxaban are less so. Most patients on DOACs starting a GLP-1 do not need any adjustment.

For patients on warfarin considering a GLP-1: this is a conversation to have with the physician who manages the warfarin, not just the one prescribing the GLP-1. The monitoring logistics matter.

Antihypertensives and dose adjustments after weight loss

Blood pressure medications are the most commonly adjusted non-glucose medications during GLP-1 therapy, and the reason is almost entirely weight loss rather than pharmacokinetic interaction.

What happens mechanistically. Weight loss of 10% or more typically reduces systolic blood pressure by 5–10 mmHg and diastolic by 3–5 mmHg, independent of any antihypertensive therapy. Patients who were on optimal doses of ACE inhibitors, ARBs, or thiazide diuretics at baseline often become relatively over-treated as they lose weight.

What this looks like in practice. Dizziness, lightheadedness on standing, and fatigue are the presenting symptoms. These are also side effects of the GLP-1 itself (via volume depletion from reduced intake and occasional GI fluid loss), which is why the presentation can be ambiguous. Home BP monitoring during GLP-1 titration is a good idea for any patient on antihypertensive therapy.

Specific medication considerations.

  • ACE inhibitors (lisinopril, enalapril) and ARBs (losartan, valsartan). No PK interaction. Dose often reduced after significant weight loss.
  • Beta-blockers (metoprolol, carvedilol). No significant PK interaction. Dose rarely needs reduction, but if the patient also loses cardiovascular reserve they may need adjustment.
  • Thiazide diuretics (HCTZ, chlorthalidone). No interaction, but thiazides can worsen volume depletion if the patient is also experiencing GI fluid loss during early GLP-1 titration.
  • Loop diuretics (furosemide). Same concern as thiazides. Volume status needs careful monitoring.
  • Calcium channel blockers (amlodipine). No interaction.

The general rule: if a patient on antihypertensive therapy is losing weight meaningfully on a GLP-1, they should be checking their blood pressure at home and having a conversation with their prescriber about dose adjustment. This is not something to discover at an emergency room visit.

Antidepressants and mood stabilizers

This category has less data than the glucose-lowering category but enough practical considerations to cover.

SSRIs (sertraline/Zoloft, escitalopram/Lexapro, fluoxetine/Prozac). No pharmacologically significant interaction. The practical consideration is that GI side effects are additive. SSRIs commonly cause nausea at initiation, and semaglutide commonly causes nausea at initiation. Starting both simultaneously is often unpleasant; stagger them by at least 4–6 weeks if possible.

SNRIs (venlafaxine/Effexor, duloxetine/Cymbalta). Same considerations as SSRIs.

Bupropion (Wellbutrin). No interaction. Of note: bupropion is a component of one of the other weight-loss drugs (Contrave, bupropion/naltrexone). Patients are not typically on both a GLP-1 and Contrave, but concurrent bupropion monotherapy with a GLP-1 is unremarkable.

Lithium. Lithium is a case where delayed gastric emptying matters more than for other psychiatric medications. Lithium has a narrow therapeutic window and is dosed to a specific blood level. GLP-1-induced changes in absorption or volume status can shift lithium levels unpredictably. Patients on lithium starting a GLP-1 should have more frequent lithium level monitoring during the first three months. Dehydration from GI side effects can rapidly raise lithium levels into the toxic range.

Benzodiazepines (alprazolam/Xanax, lorazepam/Ativan). No PK interaction, but short-acting benzodiazepines used for procedural anxiety may have unexpected onset timing due to delayed gastric emptying. Plan for this.

Atypical antipsychotics (quetiapine/Seroquel, olanzapine/Zyprexa). Metabolic effects of atypical antipsychotics include weight gain, dyslipidemia, and hyperglycemia. GLP-1 agonists are being studied specifically as adjuncts to offset antipsychotic-induced weight gain. The clinical interaction is generally favorable, with some evidence of improved metabolic outcomes. Combination therapy is managed by psychiatry.

Statins, cardiovascular drugs, and CYP metabolism

Statins are the most commonly co-prescribed medications alongside GLP-1 agonists, and the interaction picture is reassuringly uncomplicated.

Atorvastatin, rosuvastatin, simvastatin. No clinically significant interaction with any approved GLP-1 agonist. The statins and the peptides are metabolized by different pathways. The combination is extremely common in type 2 diabetes management and cardiovascular risk reduction, and is explicitly supported in professional guidelines.

The one nuance is weight loss itself. Patients who lose significant weight on a GLP-1 typically see improvements in lipid profile — LDL drops 10–20% in most patients, HDL rises modestly, triglycerides fall substantially. A patient on a statin plus a GLP-1 who loses 20% body weight may find that they could reduce or discontinue the statin entirely based on cardiovascular risk reassessment. This is a conversation for the cardiologist or primary care physician, not a self-managed decision.

Other cardiovascular drugs.

  • Aspirin (low-dose antiplatelet). No interaction.
  • Clopidogrel (Plavix). No interaction.
  • Digoxin. Theoretical concern from delayed gastric emptying and weight-based dosing. Digoxin has a narrow therapeutic window; monitoring is appropriate.
  • Amiodarone. No PK interaction with GLP-1 agonists directly, but amiodarone is itself a complex drug with many interactions; the bigger issue is usually amiodarone's interactions with everything else.

NSAIDs, opioids, and pain medication timing

NSAIDs (ibuprofen/Advil, naproxen/Aleve). No pharmacokinetic interaction. The practical concern is additive GI side effects. GLP-1 agonists commonly cause nausea and occasionally dyspepsia. NSAIDs independently cause gastric irritation and can cause ulcers with chronic use. Short courses of NSAIDs during GLP-1 therapy are generally fine; chronic daily NSAID use is less ideal and should be discussed with the prescriber.

Acetaminophen (Tylenol). No interaction. Preferred analgesic for patients on GLP-1 therapy who need pain management.

Opioids (oxycodone, hydrocodone, tramadol). No pharmacokinetic interaction, but two practical concerns. First, opioids independently slow gastric motility and cause constipation; combined with GLP-1-induced gastric emptying delay, the constipation effect can be pronounced. Second, opioids taken as short-acting preparations may have unexpectedly delayed onset due to the gastric emptying effect. Patients using opioids for acute pain control while on a GLP-1 should plan for both effects.

Corticosteroids (prednisone). Corticosteroids raise blood glucose and can blunt GLP-1 efficacy for glycemic control. Short courses (prednisone tapers for an acute exacerbation of asthma, for example) are generally fine. Prolonged corticosteroid therapy may complicate GLP-1 management and typically requires endocrinology involvement to manage the glucose swings.

Contraindications and boxed warnings

Every FDA-approved GLP-1 agonist carries specific contraindications that are not interactions with other medications but are interactions with the patient's own medical history. These are not negotiable — they are reasons the drug should not be started, regardless of what else the patient is taking.

Medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). All GLP-1 agonists carry a boxed warning regarding thyroid C-cell tumors. The warning is based on rodent studies where GLP-1 agonists caused C-cell hyperplasia and tumors. The human relevance is debated but the FDA has maintained the contraindication. Personal or family history of MTC or MEN 2 is a contraindication.

Pancreatitis history. Pancreatitis has been reported in patients on GLP-1 agonists. The causal relationship is debated — patients with type 2 diabetes and obesity have elevated baseline pancreatitis risk — but the FDA labels recommend discontinuation if pancreatitis is suspected. A prior history of pancreatitis is a relative contraindication; many prescribers will still use a GLP-1 in a patient with remote, resolved pancreatitis, but this is a specific conversation to have.

Severe gastrointestinal disease (gastroparesis, severe IBD). Delayed gastric emptying can worsen preexisting gastroparesis. Severe diabetic gastroparesis is effectively a contraindication to the GLP-1 class. Milder motility disorders may be manageable with lower doses and slower titration.

Pregnancy. All GLP-1 agonists are contraindicated in pregnancy. The labels recommend discontinuation at least two months before planned conception for semaglutide (longer half-life than shorter-acting GLP-1s). Patients who become pregnant on a GLP-1 should discontinue immediately and contact their prescriber.

Severe renal impairment. Dose adjustments and caution are needed for patients with eGFR below specific thresholds. The thresholds vary by specific GLP-1; the prescribing information is specific for each product.

These are not interactions in the classical sense, but they are the most important safety considerations in the GLP-1 class and must be addressed before any interaction-level questions become relevant.

How to have the conversation with your physician

The practical question for most patients is not "what is the mechanism of the interaction" but "what do I say to my doctor." A few framings that tend to produce useful conversations:

Before starting. Bring a complete list of every medication, supplement, and over-the-counter product. The pharmacist is often the best resource for this — ask for a printout of your active prescriptions. Mention anything you take "as needed" (PRN anxiety medications, migraine medications, NSAIDs) because these are often left off medication lists.

Ask specifically about:

  • Whether any of your current medications' doses should be pre-adjusted before the GLP-1 is started.
  • What monitoring (lab tests, home BP, blood glucose) should happen during the first three months.
  • Whether any of your medications will need adjustment as you lose weight (this includes levothyroxine, warfarin, antihypertensives, antiseizure drugs, and some psychiatric medications).
  • What GI side effects are expected and at what severity they should trigger a call to the office.

During titration. Flag anything that feels unusual — not just side effects, but also unexpected changes in the efficacy or timing of your other medications. A patient who notices that their morning thyroid medication feels different or that their antidepressant timing feels off should mention it. These are often the first signals that a dose adjustment is needed.

At steady state. Once the GLP-1 dose is stable and weight has plateaued, revisit the medication list again. Many patients end up able to reduce or discontinue antihypertensives, statins, and some psychiatric medications based on changes in their underlying risk profile. This is a long-term reassessment that often gets skipped.

A pharmacist consultation — separate from the prescribing physician visit — is often the highest-value step in this process. Community pharmacists are trained specifically in drug-drug interactions, often have more time than the prescriber, and can review the entire medication list in one focused conversation. This is an underused resource in the US healthcare system.

A note about compounded GLP-1s

Everything in this article applies to FDA-approved GLP-1 agonists: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon).

It also generally applies to compounded versions of these drugs when produced by properly operating §503A or §503B pharmacies using the same active pharmaceutical ingredient at the same concentrations. The drug is the same molecule; the interaction profile is the same.

What does not necessarily apply: compounded GLP-1 products sold with added B-vitamins, amino acids, or other ingredients as "enhanced" formulations. The FDA's post-shortage compounding landscape, covered in detail in The Compounded GLP-1 Crisis, includes a substantial market of such combinations. The interaction profiles of these additions are not formally characterized, and the interaction between the added ingredients and the patient's other medications may not be in any database. Patients on these formulations should be especially cautious and especially transparent with their prescribers about what is in the vial.

Directly imported overseas GLP-1 products — covered in The Overseas Channel — have additional quality concerns (dosage accuracy, contamination) that are separate from interaction questions but compound the safety picture.

For interaction purposes, the safe assumption is: the approved-drug interaction profile applies to the active ingredient. It does not necessarily apply to whatever else is in the vial. If you are on a compounded formulation and on other prescription medications, flag this to your prescriber and pharmacist explicitly.

Sources

  1. FDA. Prescribing information, Ozempic (semaglutide injection). fda.gov
  2. FDA. Prescribing information, Wegovy (semaglutide injection). fda.gov
  3. FDA. Prescribing information, Mounjaro (tirzepatide injection). fda.gov
  4. FDA. Prescribing information, Zepbound (tirzepatide injection). fda.gov
  5. FDA. Prescribing information, Rybelsus (semaglutide oral). fda.gov
  6. FDA. Prescribing information, Egrifta (tesamorelin). fda.gov
  7. American Diabetes Association. Standards of Care in Diabetes — 2026. diabetesjournals.org
  8. Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity. Postgrad Med. 2022.
  9. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art. Mol Metab. 2021.
  10. Lexicomp drug interaction monographs (subscription; accessed 2026).
  11. Clinical Pharmacology (Elsevier; subscription; accessed 2026).
  12. FDA Drug Shortage List and FDA Declaratory Orders on tirzepatide (Dec 2024) and semaglutide (Feb 2025).
  13. US Pharmacopeial Convention. General chapters on dose uniformity and labeling for compounded products.

This article is educational and does not constitute medical advice. Drug interactions are highly individual and depend on specific dosing, patient history, concurrent conditions, and pharmacogenetic factors that cannot be addressed in a general reference. Always consult a licensed pharmacist or prescribing clinician before combining peptides with prescription medications, and before making any dose adjustments to existing medications based on what you read here. If you are experiencing adverse effects that may be related to a drug interaction, contact your prescriber or pharmacist promptly.

For a searchable database of documented peptide-drug interactions — including non-GLP-1 peptides such as BPC-157, TB-500, CJC-1295/Ipamorelin, and PT-141 — see our Peptide-Drug Interaction Database.

Disclaimer

This article is for educational purposes only and does not constitute medical advice. Consult a licensed medical professional before considering any peptide therapy.

← All articles